Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

RADICALS-HD trial: androgen deprivation therapy with post-operative...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell...

Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy ( Dr Robert Motzer - Memorial Sloan Kettering Cancer Center, New York, USA )

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...

Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )

Hyperthermic intraperitoneal chemo for locally advanced colon cancer

Dr Álvaro Arjona-Sánchez- Reina Sofia University Hospital, Cordoba, Spain

Hyperthermic intraperitoneal chemo for locally advanced colon cancer ( Dr Álvaro Arjona-Sánchez- Reina Sofia University Hospital, Cordoba, Spain )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Lasofoxifene shows promise for women with ESR1-mutated mBC

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

New data presented at ESMO for multi-cancer early detection

Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences

New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )

Perioperative nivolumab did not improve RFS in RCC patients at high risk for...

Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )

Nirogacestat demonstrates clinically significant improvement in PFS versus...

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany

Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )

More from ecancer